In a nutshell This study looked at how effective a blood test was at predicting future outcomes in patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that the lymphocyte-to-monocyte ratio blood test is very effective at predicting future outcomes for patients with relapsed or difficult to treat diffuse large...
Read More
In a nutshell The authors looked at the effect of radiation therapy after autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that radiation therapy after autologous stem cell transplantation improved time to disease progression. Some background Hodgkin lymphoma (HL) is generally...
Read More
In a nutshell This study looked at the use of lenalidomide (Revlimid) treatment for patients with relapsed mantle cell lymphoma. The authors concluded that lenalidomide is generally safe and effective for treating patients with advanced stage relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is an...
Read More
In a nutshell This article reviewed the use of obinutuzumab for patients with follicular lymphoma who have failed rituximab treatment. The article concluded that obinutuzumab treatment is useful for follicular lymphoma patients who have not responded well to rituximab regimens. Some background Follicular lymphoma (FL) is a common type...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of an ibrutinib (Imbruvica) and rituximab (Rituxan) combination in treating patients with relapsed or refractory mantle cell lymphoma (MCL) or newly diagnosed elderly patients. The primary objective will be measured by the response rate. This trial is being conducted...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of copanlisib (BAY 80-6946) with a standard immunochemotherapy (R-CHOP or R-B) compared to immunochemotherapy alone in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the time to disease progression and the maximum...
Read More
In a nutshell This study looked at the use of brentuximab vedotin (Adcetris), nivolumab (Opdivo), and pembrolizumab (Keytruda) in treating patients with relapsed or refractory Hodgkin lymphoma. The study concluded that all three medications are very effective at treating patients with relapsed or refractory Hodgkin lymphoma. Some...
Read More
In a nutshell This phase 1 clinical trial will test the safety of JCAR017 CAR T-cells in treating patients with relapsed or refractory (unresponsive to treatment) B-cell non-Hodgkin’s lymphoma. The primary outcome with be measured by adverse (negative) side effects, maximum dosage, response rate, and concentration of JCAR017. The...
Read More
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of polatuzumab vedotin with obinutuzumab (Gazyva) and venetoclax (Venclexta) in patients with relapsed or refractory follicular lymphoma (FL) or rituximab (Rituxan) with polatuzumab vedotin and venetoclax in patients with relapsed or refractory diffuse large B-cell...
Read More
In a nutshell This phase 2 clinical trial will determine the effectiveness of denintuzumab mafodotin (SGN-CD19A) with RICE chemotherapy in patients with relapsed or refractory (unresponsive to treatment) diffuse large B-cell lymphoma (DLBCL) or stage 3b follicular lymphoma (FL). The primary outcome will be measured by the complete remission...
Read More
